BBL

Sciton Inc. Launches Revolutionary BBL HEROic: A New Era in Pulsed Light Technology

Retrieved on: 
Monday, April 8, 2024
Freedom, Brain, BBL, Intelligence, Skin, PALO, ICTM, Patient safety, Product management, Intelligent control, Oil

Emphasizing patient safety, the technology simplifies the training process for new or less experienced technicians without compromising patient outcomes.

Key Points: 
  • Emphasizing patient safety, the technology simplifies the training process for new or less experienced technicians without compromising patient outcomes.
  • Kathy Ziegler, Director of Product Management at Sciton, shared her enthusiasm: "BBL HEROic is set to redefine the pulsed-light industry.
  • Sciton will host six regional seminars across the country, offering providers an in-depth look at BBL HEROic, complete with hands-on demonstrations.
  • For more information on BBL HEROic or to register for a seminar, visit www.bblheroic.com .

LBank Exchange Will List beoble (BBL) on February 28, 2024

Retrieved on: 
Tuesday, February 27, 2024
Privacy, API, Dapp, IPFS, Friction, BBL, Ecosystem, Messenger, Communication, Cryptocurrency

LBank Exchange is thrilled to announce the upcoming listing of beoble (BBL), representing a pioneering venture into the realm of Web3 communications, positioning itself as a bridge for the web3 community to interact seamlessly and securely.

Key Points: 
  • LBank Exchange is thrilled to announce the upcoming listing of beoble (BBL), representing a pioneering venture into the realm of Web3 communications, positioning itself as a bridge for the web3 community to interact seamlessly and securely.
  • Through its web-based chat application, beoble enables users to engage in wallet-to-wallet communications, ensuring that every message sent and received is end-to-end encrypted.
  • Beyond serving individual users, beoble extends its capabilities as a comprehensive toolkit for developers, offering a suite of APIs and SDKs designed for swift integration into decentralized applications (Dapps).
  • At its core, beoble is committed to a no-compromise approach towards privacy, security, and user experience.

Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara®

Retrieved on: 
Thursday, February 29, 2024
Psoriatic arthritis, Ulcerative colitis, Crohn's disease, Psoriasis, Ustekinumab, Trademark, FDA, Patent, Johnson & Johnson, BLA, Inflammation, IPR, PTAB, Inter partes review, Patient, Science, BBL, Pharmaceutical industry

The agreement licenses the Company to launch in the United States, in February 2025, once approved by the U.S. FDA.

Key Points: 
  • The agreement licenses the Company to launch in the United States, in February 2025, once approved by the U.S. FDA.
  • The U.S. FDA has accepted the Company's Biologics License Application (BLA) for Bmab 1200 (bUstekinumab) for review under the 351(k) pathway.
  • Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd, said: "This settlement agreement reflects our commitment and focus on science and innovation.
  • As a fully integrated biosimilars company, Biocon Biologics is committed to expanding access to life-changing treatments with our broad portfolio of products."

Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

Retrieved on: 
Friday, February 9, 2024
PBS, Novartis, Partnership, Trastuzumab, Cancer, BBL, Patient, Generic drug

BENGALURU, India, Feb. 8, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD$35 million1) and biosimilar Bevacizumab (market value of AUD$45 million2) in Australia.

Key Points: 
  • BENGALURU, India, Feb. 8, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD$35 million1) and biosimilar Bevacizumab (market value of AUD$45 million2) in Australia.
  • Under the agreement, Sandoz will distribute the Biocon Biologics' brands, OGIVRI® (bTrastuzumab) and ABEVMY® (bBevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pharmaceutical company to patients in Australia.
  • Trastuzumab is a biosimilar of Herceptin® and Bevacizumab is a biosimilar of Avastin®3 – both biosimilars are available on the PBS and utilised for the treatment of various cancers.
  • OGIVRI® and ABEVMY® are registered trademarks of Biosimilars Newco Limited, a Biocon Biologics Company.

Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

Retrieved on: 
Friday, February 9, 2024
PBS, Novartis, Partnership, Trastuzumab, Cancer, BBL, Patient, Generic drug

BENGALURU, India, Feb. 8, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD$35 million1) and biosimilar Bevacizumab (market value of AUD$45 million2) in Australia.

Key Points: 
  • BENGALURU, India, Feb. 8, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD$35 million1) and biosimilar Bevacizumab (market value of AUD$45 million2) in Australia.
  • Under the agreement, Sandoz will distribute the Biocon Biologics' brands, OGIVRI® (bTrastuzumab) and ABEVMY® (bBevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pharmaceutical company to patients in Australia.
  • Trastuzumab is a biosimilar of Herceptin® and Bevacizumab is a biosimilar of Avastin®3 – both biosimilars are available on the PBS and utilised for the treatment of various cancers.
  • OGIVRI® and ABEVMY® are registered trademarks of Biosimilars Newco Limited, a Biocon Biologics Company.

Face Expert Dr. Georges J. Samaha Joins Exclusive Haute Beauty Network

Retrieved on: 
Wednesday, January 31, 2024
Augmented fifth, Surgeon, Breast augmentation, Mount Sinai Hospital, Alpha Omega Alpha, Family, Breast, Travel, Plastic surgery, AOA, Rhinoplasty, Patient, Philosophy, Plastic, FDA, Johns Hopkins Hospital, Nobel Prize, Journal, BBL, University, Beauty, Medicine, Textbook, Craniofacial, Mastopexy, Hospital, Dentistry

NEW YORK, Jan. 31, 2024 /PRNewswire-PRWeb/ -- Dr. Georges Samaha is double-board certified by the American Board of Plastic Surgery. He is a diplomate of the American Board of Plastic Surgery as well as a diplomate of the American Board of Surgery. Dr. Samaha has specific interests in various aspects of facial plastic surgery — including deep plane facelift, neck lift, rhinoplasty, and eyelid rejuvenation — as well as breast and body contouring procedures. Patients travel from around the world for the above procedures including breast augmentation, breast lifts, high-definition tummy tucks, natural buttock augmentation using fat transfer known as the Brazilian Butt Lift ("BBL"), and his special natural high-definition liposuction with abdominal etching technique. Dr. Samaha's array of popular procedures can provide patients with beautiful, natural curves and are truly life-changing.

Key Points: 
  • Dr. Georges J. Samaha joins Haute Beauty Network as a face expert representing the Miami, FL market.
  • NEW YORK, Jan. 31, 2024 /PRNewswire-PRWeb/ -- Dr. Georges Samaha is double-board certified by the American Board of Plastic Surgery.
  • He is a diplomate of the American Board of Plastic Surgery as well as a diplomate of the American Board of Surgery.
  • Dr. Samaha has specific interests in various aspects of facial plastic surgery — including deep plane facelift, neck lift, rhinoplasty, and eyelid rejuvenation — as well as breast and body contouring procedures.

THE AMERICAN ACADEMY OF COSMETIC SURGERY (AACS) MARKS ITS 40th ANNIVERSARY WITH A COMPREHENSIVE SCIENTIFIC MEETING, PRE-MEETING WORKSHOP, AND DIVERSE OFFERINGS

Retrieved on: 
Tuesday, January 16, 2024
BBL, Dermatology, Research, Nutrition, Accreditation, Greatest, Surgeon, AACS, Lecture, ASM, General surgery, Hilton New Orleans Riverside, Practice management, Safety, Otorhinolaryngology, Plastic surgery, DMD, MPH, Breast, Education, Fountain of Youth, Physician, Immediate, American Journal, Elective surgery, Female, Male, Woman, Mortality, CME, Patient, Allied health professions, Rhinoplasty, Tropical medicine, Continuing medical education, Ophthalmology, Disease, DRS, American Academy, Public health, All, Patient safety, Dentistry

CHICAGO, Jan. 16, 2024 /PRNewswire/ -- The American Academy of Cosmetic Surgery (AACS), the world's largest multi-specialty home for physicians dedicated to cosmetic surgery and aesthetic medicine, will present its 40th Annual Scientific Meeting (ASM) on February 22-24, 2024, with an optional pre-meeting workshop on Ultrasound for Safe Brazilian Butt Lift Surgery and More, on Wednesday, February 21.

Key Points: 
  • In celebration of the AACS' 40th Annual Scientific Meeting, and the 40-year anniversary of the formation of the Academy and its official publication, The American Journal of Cosmetic Surgery, the meeting includes a comprehensive scientific program, as well as an array of advocacy, enrichment, networking and 40th anniversary celebratory activities.
  • Offering 41 educational sessions , the 2024 AACS ASM features foremost experts spanning diverse background specialties, such as dermatology, otolaryngology, general surgery, oral, and maxillofacial surgery, ophthalmology, and plastic and reconstructive surgery.
  • J. Kevin Duplechain, MD, FAACS, cosmetic surgeon and Immediate Past-President of the AACS and Cosmetic Surgery Foundation, will deliver the prestigious Webster Lecture on Friday, February 23.
  • Cosmetic surgery practitioners may register here for the 2024 AACS ASM.

Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe

Retrieved on: 
Thursday, November 30, 2023
Insulin glargine, BBL, Acquisition, Health, White paper, Etanercept, Ophthalmology, Insulin aspart, Patient, Adalimumab

BENGALURU, India, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris’ biosimilars business in 31 European countries has been successfully completed.

Key Points: 
  • BENGALURU, India, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris’ biosimilars business in 31 European countries has been successfully completed.
  • In Europe, Biocon Biologics portfolio includes 7 biosimilars: Insulin Aspart and Insulin Glargine, Bevacizumab, Pegfilgrastim, Trastuzumab, Adalimumab, and Etanercept.
  • At a global level, Biocon Biologics has a robust pipeline of 20 assets for diabetology, oncology, immunology, ophthalmology, and bone health.
  • Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd, said: “The integration of the Viatris’ biosimilar business in Europe ahead of schedule is another important milestone for Biocon Biologics in our journey as a global biosimilars leader.

Four Nails in the $100-Per-Barrel-Oil-by-December Coffin, an Industrial Info News Alert

Retrieved on: 
Wednesday, December 13, 2023
Oil, Gas, Energy, Hamas, WTI, BBL, Hydrocarbon, Research, Hope, EIA, International Energy Agency, Baby boomers, IIR, USD, Christmas, West Texas Intermediate, News, GMI, IEA, Gasoline, Cryptocurrency, Renewable energy, Great Lakes Paper

Specifically, Industrial Info's Hillary Stevenson says, "With oil being a global commodity, it's no secret that macroeconomics are making the biggest impact."

Key Points: 
  • Specifically, Industrial Info's Hillary Stevenson says, "With oil being a global commodity, it's no secret that macroeconomics are making the biggest impact."
  • Also, adds Industrial Info's Geoffrey S. Lakings, demand in the U.S. and pretty much everywhere else is failing to live up to expectations.
  • Industrial Info Resources (IIR) is the leading provider of industrial market intelligence.
  • Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries.

Board Certified Plastic Surgeon, Dr. Alfred Sofer announces its new surgery center at 311 North Street

Retrieved on: 
Thursday, November 16, 2023
Breast augmentation, Mastopexy, BBL, PC, Safety, Patient, Plastic surgery, Heart, Patient satisfaction, Dentistry, Nursing

WHITE PLAINS, N.Y., Nov. 16, 2023 /PRNewswire/ -- Bella Mae Plastic Surgery, PC and board certified plastic surgeon, Dr. Alfred Sofer proudly announces the grand opening of its cutting-edge, QUADA accredited facility in the heart of White Plains, NY.

Key Points: 
  • WHITE PLAINS, N.Y., Nov. 16, 2023 /PRNewswire/ -- Bella Mae Plastic Surgery, PC and board certified plastic surgeon, Dr. Alfred Sofer proudly announces the grand opening of its cutting-edge, QUADA accredited facility in the heart of White Plains, NY.
  • Boasting state-of-the-art technology and a team of highly skilled professionals, Bella Mae Plastic Surgery is set to redefine the cosmetic surgery experience in the region.
  • At the helm of Bella Mae Plastic Surgery is well-known board-certified by the American Board of Plastic Surgery, Dr. Alfred Sofer , renowned for his expertise and dedication to patient satisfaction.
  • For inquiries, consultations, or to learn more about Bella Mae Plastic Surgery and its services, please contact: